Article
A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Cancer imaging : the official publication of the International Cancer Imaging Society - 20 Jan 2023
Lu Chia-Feng, Liao Chien-Yi, Chao Heng-Sheng, Chiu Hwa-Yen, Wang Ting-Wei, Lee Yen, Chen Jyun-Ru, Shiao Tsu-Hui, Chen Yuh-Min, Wu Yu-Te
Abstract excerpt
BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for non-small cell lung cancer (NSCLC) with EGFR mutations. Approximately half of the patients with EGFR-mutated NSCLC are treated with EGFR-TKIs and develop disease progression within 1 year. Therefore, the early prediction of tumor progression in patients who receive EGFR-TKIs can facilitate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.